Toggle navigation
Home
Search
Services
Blog
Contact
About
Aptamers as Cellular Targeting Agents
Schmittgen, Thomas D.
Washington State University, Pullman, WA, United States
Search 28 grants from Thomas Schmittgen
Search grants from Washington State University
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Publications
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
The Effect of TCF7L2 on Glucose Metabolism
Binding Stoichiometry of Fg-Nups and Karyopherins
AAV Gene Therapy for Alzheimer's Disease
Core - Data Management and Statistics
HI in the Local Universe
Recently added grants:
Mechanisms controlling distal nephron maturation
Functional analysis of SBP2 and selenocysteine incorporation
Regulation of experience-dependent cortical circuit development by MEF2C and genes linked to neurodevelopmental disorders
Exosome Based Placental Maternal Communication
'Two year outcomes after dextrose gel prophylaxis for neonatal hypoglycaemia'
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA081396-02
Application #
6174299
Study Section
Diagnostic Radiology Study Section (RNM)
Program Officer
Menkens, Anne E
Project Start
1999-04-01
Project End
2002-07-16
Budget Start
2000-04-01
Budget End
2002-07-16
Support Year
2
Fiscal Year
2000
Total Cost
$141,519
Indirect Cost
Institution
Name
Washington State University
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
041485301
City
Pullman
State
WA
Country
United States
Zip Code
99164
Related projects
NIH 2000
R21 CA
Aptamers as Cellular Targeting Agents
Schmittgen, Thomas D. / Washington State University
$141,519
NIH 1999
R21 CA
Aptamers as Cellular Targeting Agents
Schmittgen, Thomas D. / Washington State University
Publications
Schmittgen, Thomas D; Teske, Sabine; Vessella, Robert L et al.
(2003)
Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients.
Int J Cancer 107:323-9
Comments
Be the first to comment on Thomas Schmittgen's grant